Actively Recruiting

Age: 18Years +
All Genders
ID06025240

Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients

Led by Liverpool University Hospitals NHS Foundation Trust · Updated on 2024-08-30

282

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

Sponsors

L

Liverpool University Hospitals NHS Foundation Trust

Lead Sponsor

K

Kidney Research United Kingdom

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating a new blood test to detect antibodies that may form after kidney transplant. These antibodies can be hard to identify because they cause no symptoms but can damage the kidney. The study compares this new test with existing antibody tests to see how well it detects antibody-related inflammation versus other types of inflammation like urinary tract infections. It also investigates whether patients over 60 years old are less likely to experience immune reactions, such as rejection, compared to younger patients. The findings could help tailor immunosuppression treatments based on patient age groups to reduce risks associated with these drugs. The study involves three main parts: a cf-DNA arm where high-risk kidney transplant patients receive a blood test measuring donor-derived cell-free DNA between 6 to 12 months post-transplant alongside standard tests; monitoring immunological events and antibody formation in patients younger and older than 60 through routine sample collection; and developing machine learning predictive models for antibody formation in unsensitized patients within one year of transplant. Blood, urine, and ultrasound tests are part of routine care and used for research without extra visits. Participants will provide samples during regular outpatient visits, including blood for the new cf-DNA test and standard monitoring tests such as donor-specific antibodies and viral PCRs. The study tracks outcomes like antibody development, infections, graft function, and patient survival over about one year. Researchers also use machine learning to identify who is most at risk for antibody formation. No extra hospital visits beyond usual care are expected, and all testing aligns with routine post-transplant monitoring schedules.

CONDITIONS

Brief Title

Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients transplanted within 6-12 months or admitted for renal transplant within the first 6 months
  • Patients must have capacity to provide informed consent
  • Patients must have received a high-risk transplant defined as level 4 mismatch, cRF >20%, second or subsequent transplant, ABO or HLA incompatible
  • Any adult patient with capacity undergoing or within 72 hours of a renal transplant
  • Unsensitized patients pre-transplant for predictive model study
Not Eligible

You will not qualify if you...

  • Patients transplanted for longer than 12 months
  • Patients with low risk transplants
  • Patients lacking capacity to consent
  • Patients transplanted longer than 2 weeks for older age immunological events and predictive model studies
  • Sensitized patients for predictive model study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) during a routine outpatient appointment

Monitoring

Duration - Up to 1 year

Participants who have received a renal transplant are monitored through routine outpatient visits. Blood and urine samples are collected, and clinical evaluations are performed to assess immunological events and antibody formation.

Regular outpatient visits for routine post-transplant care with blood and urine tests

Diagnostic Evaluation

Duration - Single assessment at 6 to 12 months post-transplant

Participants deemed high-risk post-transplant have additional blood sampling to test donor-derived cell-free DNA (dd-cfDNA) alongside standard care tests to detect graft injury and antibody-mediated rejection.

1 visit (blood sample and ultrasound) during routine post-transplant testing

Long-term Monitoring

Duration - Up to 1 year following transplant

Participants continue to be observed with assessments including antibody monitoring and clinical outcomes collection to evaluate immunological events and graft function over time.

Multiple visits aligned with routine outpatient care

Trial Site Locations

Total: 1 location

1

Liverpool University Hospitals NHS Foundation Trust

Liverpool, Merseyside, United Kingdom, L7 8YE

Actively Recruiting

Loading map...

Research Team

G

George E Nita, MBChB MSc MRCSEd

P

Petra M Goldsmith, MBBChir PhD FRCS

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here